Skip to content

Study · Randomized controlled trial · n = 94 · 2018

8 results

Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.

McClung MR, Harvey NC, Fitzpatrick LA, Miller PD, Hattersley G, Wang Y, Cosman F

Menopause (New York, N.Y.)1 Jul 2018Cited by 30 (Europe PMC)

PMID29462094 (opens in a new tab)PMCIDPMC6015760 (opens in a new tab)DOI10.1097/gme.0000000000001080 (opens in a new tab)PepBankPUB-29462094
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women aged 80 or older, abaloparatide numerically reduced vertebral fracture risk versus placebo, without statistical significance.

    In plain wordsIn women aged 80 or older, vertebral fracture risk was numerically lower with abaloparatide than placebo, but the difference was not significant.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeVertebral fracture risk
    Study

    n = 94

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Abaloparatide therapy was associated with numerical, but not statistically significant, reductions in the risk of vertebral and nonvertebral fractures in this subpopulation, compared with placebo.
    2 context sentences
    Summary · context
    The mean ages of the women ≥80 years were 81.9 and 81.7 years in the placebo (n = 43) and abaloparatide (n = 51) groups, respectively.
    Summary · context
    This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.MethodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women aged 80 or older, abaloparatide numerically reduced nonvertebral fracture risk versus placebo, without statistical significance.

    In plain wordsIn women aged 80 or older, nonvertebral fracture risk was numerically lower with abaloparatide than placebo, but the difference was not significant.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeNonvertebral fracture risk
    Study

    n = 94

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Abaloparatide therapy was associated with numerical, but not statistically significant, reductions in the risk of vertebral and nonvertebral fractures in this subpopulation, compared with placebo.
    2 context sentences
    Summary · context
    The mean ages of the women ≥80 years were 81.9 and 81.7 years in the placebo (n = 43) and abaloparatide (n = 51) groups, respectively.
    Summary · context
    This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.MethodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.
  3. 03HumanRandomized controlled trialSafety outcome

    In women aged 80 or older, adverse event proportions were similar with abaloparatide and placebo.

    In plain wordsIn women aged 80 or older, adverse event rates were similar with abaloparatide and placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeAdverse event proportions between treatment groups
    Study

    n = 94

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The proportion of participants reporting adverse events was similar between treatment groups and between the older subgroup and the overall population.
    2 context sentences
    Summary · context
    The mean ages of the women ≥80 years were 81.9 and 81.7 years in the placebo (n = 43) and abaloparatide (n = 51) groups, respectively.
    Summary · context
    This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.MethodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women aged 80 or older, abaloparatide increased total hip BMD from baseline.

    In plain wordsIn women aged 80 or older, abaloparatide increased hip bone density from baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD
    Study

    n = 51

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Measurements

    BMD increase
    3.9%
    total hip at 18 months

    Source sentences

    Summary
    The increases in BMD from baseline to 18 months with abaloparatide treatment were 3.9% at the total hip (P < 0.001), 3.6% at the femoral neck (P < 0.01), and 12.1% at the lumbar spine (P < 0.001), and were similar to those observed in the overall population.
    2 context sentences
    Summary · context
    The mean ages of the women ≥80 years were 81.9 and 81.7 years in the placebo (n = 43) and abaloparatide (n = 51) groups, respectively.
    Summary · context
    This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.MethodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women aged 80 or older, abaloparatide increased femoral neck BMD from baseline.

    In plain wordsIn women aged 80 or older, abaloparatide increased femoral neck bone density from baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck BMD
    Study

    n = 51

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Measurements

    BMD increase
    3.6%
    femoral neck at 18 months

    Source sentences

    Summary
    The increases in BMD from baseline to 18 months with abaloparatide treatment were 3.9% at the total hip (P < 0.001), 3.6% at the femoral neck (P < 0.01), and 12.1% at the lumbar spine (P < 0.001), and were similar to those observed in the overall population.
    2 context sentences
    Summary · context
    The mean ages of the women ≥80 years were 81.9 and 81.7 years in the placebo (n = 43) and abaloparatide (n = 51) groups, respectively.
    Summary · context
    This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.MethodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women aged 80 or older, abaloparatide increased lumbar spine BMD from baseline.

    In plain wordsIn women aged 80 or older, abaloparatide increased spine bone density from baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 51

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Measurements

    BMD increase
    12.1%
    lumbar spine at 18 months

    Source sentences

    Summary
    The increases in BMD from baseline to 18 months with abaloparatide treatment were 3.9% at the total hip (P < 0.001), 3.6% at the femoral neck (P < 0.01), and 12.1% at the lumbar spine (P < 0.001), and were similar to those observed in the overall population.
    2 context sentences
    Summary · context
    The mean ages of the women ≥80 years were 81.9 and 81.7 years in the placebo (n = 43) and abaloparatide (n = 51) groups, respectively.
    Summary · context
    This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.MethodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women aged 80 or older, abaloparatide BMD gains were similar to those in the overall population.

    In plain wordsIn women aged 80 or older, abaloparatide bone density gains were similar to those in the overall population.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBMD response by age population
    Study

    n: not reported in source

    Comparator
    Overall population
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The increases in BMD from baseline to 18 months with abaloparatide treatment were 3.9% at the total hip (P < 0.001), 3.6% at the femoral neck (P < 0.01), and 12.1% at the lumbar spine (P < 0.001), and were similar to those observed in the overall population.
    1 context sentence
    Summary · context
    This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.MethodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.

Studies that did not test the peptide alone1

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 08HumanNot a test of Abaloparatide (Tymlos) aloneRandomized controlled trialSafety outcome

    In ACTIVE, adverse event proportions were similar in the older subgroup and overall population.

    In plain wordsIn ACTIVE, adverse event rates were similar in the oldest women and the overall population.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeAdverse event proportions by age population
    Study

    n: not reported in source

    Comparator
    Overall population
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    The proportion of participants reporting adverse events was similar between treatment groups and between the older subgroup and the overall population.
    1 context sentence
    Summary · context
    This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.MethodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.